Theme: Exploring the Recent Trends & Advances in the Field of Pharma Research and Innovations in Pharma Industry
Pharma Research 2019
- Why to Attend
- Past Conferences
- Past Conference Report
- Keynote Speakers
- Past Conference Chairs/Co-Chairs
- Past Conference Moderators
- Media Partners
- Market Analysis
- Letter of Invitation
- Visa Application
For developing a new medicine it will take nearly 10-15 years and on average and costs an average of $2.6 billion. In discovery procedure comprises the initial stages of research, which are intended to recognize an investigational drug and perform primary tests in the lab. This first stage of the process takes three to six years. By the end, investigators hope to identify a capable drug aspirant to further study in the lab and in animal models, and then in people. These developments offer great ability, but also add complexity to the R&D process. In order to ensure the safety and efficacy of personalized therapies that are used along with diagnostics, clinical trial protocols must be improved and increased.
Track: 2 : Formulations and NNDS:
The drug delivery technology market is expected to reach USD 1,504.7 Billion by 2020 from USD 1,048.1 Billion in 2016, growing at a CAGR of 7.5% from 2015 to 2020. The global market for Novel Drug Delivery Systems (NDDS) is expected to hit USD 320 billion by the year 2021. With the rising number of patients suffering from different types of cancer, favorable reimbursement scenario in US, improved and advanced healthcare infrastructure have driven North America to become the leading regional segment in the global NDDS in cancer therapy market. Among the NDDS technologies Embolization of Particles, Selective Internal Radiation Therapy (SIRT), Holmium-based Microspheres, Liquid Embolics and Nanoparticles are gaining importance from market point of view.
In 2018 FDA has approved 34 new drugs which are presently in the market. Each year, CDER approves series of new drugs and biological products. Some of these products are often innovative new products that never before have been used in clinical practice. FDA’s classification of a drug as an “NME” for review purposes is distinct from FDA’s determination of whether a drug product is a “new chemical entity” or “NCE” within the meaning of the Federal Food, Drug, and Cosmetic Act. According to Medscape the ratio of researched drugs to eventually approved therapies at between 5,000-to-1 and 10,000-to-1. Nonetheless, if a drug manages to gain FDA approval, the cumulative direct and indirect expenses are huge. As per estimated study performed by a well-known university, the true cost to bring a drug to market was US$2.56 billion. This figure is inclusive of just shy of $1.4 billion in average out-of-pocket costs to the drug developer, as well as $1.16 billion in time costs, which are essentially the expected returns that investors forgo while a drug is in development.
The API market in the US is as expected growing at a CAGR of 7% over the period 2014-2019. The market research and analysis estimates that in terms of geographic regions, the Americas will be the major revenue contributor to the active pharmaceutical ingredients market throughout the next four years. The increasing demand for generic drugs from countries such as the US, the growth in aging population, and the presence of an organized R&D structure for drug development are some of the major factors that will drive the growth of the market in this region. The key vendors in this sector are Abbott Laboratories, Aurobindo Pharma, Mylan and Teva Pharmaceutical Industries.
“The Quality cannot be tested into the product, but it should be built into it.” QbD can be attributed as a Scientific, risk-based, holistic and proactive approach to the development of a pharmaceutical product. It is more of a deliberate design effort from product conception through commercialization requiring full understanding of how product attributes and process would relate to product performance. In FDA’s Office of New Drug Quality Assessment (ONDQA), a new risk-based pharmaceutical quality assessment system (PQAS) was established based on the application of product and process understanding. The difference between QbD for NDA and ANDA products is most apparent at the first step of the process. For an NDA, the target product profile is under development while for the ANDA product the target product profile is well established by the labeling and clinical studies conducted to support the approval of the reference product.
Good Manufacturing Practice is the part of quality management which ensures that products are consistently produced and controlled according to the quality standards appropriate to their intended use and as required by the marketing authorization, clinical trial authorization or product specification. Good Manufacturing practices conference aims at both production and Quality Control. Current Good Manufacturing Practices (cGMP) is aimed primarily at managing and minimizing the risks inherent in pharmaceutical manufacture to ensure the quality, safety and efficacy of products. FDA regulates the quality of pharmaceuticals very carefully. Current Trends in the FDA is the main regulatory standard for ensuring pharmaceutical quality.
Regulatory affairs is a comparatively new profession which developed from the desire of governments to protect public health by controlling the safety and efficacy of products in areas including pharmaceuticals , veterinary medicines, medical devices, pesticides, agrochemicals, cosmetics and complementary medicines. Regulatory Affairs is involved in the development of new medicinal products from early on, by integrating regulatory principles and by preparing and submitting the relevant regulatory dossiers to health authorities. Regulatory Affairs is actively involved in every stage of development of a new medicine and in the post-marketing activities with authorized medicinal products. The Regulatory Affairs department is an important part of the organizational structure of pharmaceutical industry. Internally it liaises at the interphase of drug development, manufacturing, marketing and clinical research. Externally it is the key interface between the company and the regulatory authorities.
The biopharmaceutical sector in US enjoys 17% of all domestic R&D funded by the country and in return gave $2.5 trillion cumulative addition in economic output in 2016. Companies engaged in the brand name pharmaceutical manufacturing have grappled in recent years owing to the largest waves of drug patent expirations in history. As a consequence enabling low-price generic drugs to inundate the market. Many brand name pharmaceutical manufacturers have contended with intensifying competition from generic manufacturers, cutting into revenue growth. Until the next the five years till 2022, investments in research and development that generate a high return will occur as many pharmaceutical manufacturers strengthen their drug pipeline with orphan drugs.
Recently, process engineers have shown inclination to single-use, modular and continuous manufacturing technologies to improve efficiency and minimize scale-up and technology transfer challenges in the pharmaceutical industry. Lot of these innovations are driven by updates instigated by the FDA. The changes are inevitable; especially in the already aging biopharmaceutical sector of the industry, where original processes are often overly complex, and are characterized by inefficiency, and occasionally, inherent unpredictability.
With greater attention to the following elements this session will discuss the all the key lookouts essential for the development of a QA/QC system in pharmaceutical manufacturing process and requires implementation in tracking inventory compilation:
An inventory agency responsible for coordinating QA/QC activities;
A QA/QC plan;
General QC procedures
Source category-specific QC procedures
QA review procedures;
Reporting, documentation, and archiving procedures.
Chromatography and MS are extensively used in the formulation development stage of generic drug products. The ICH Q3B guidelines address the reporting threshold, identification threshold, and qualification threshold for impurities in the drug product. Chromatography (LC) and Gas Chromatography (GC) are extensively used to analyze stable compounds. However, for labile compounds require derivatization prior to LC or GC analysis. For certain selected analyses, Liquid Chromatography- Ultraviolet Detection (LC-UVD) and Gas Chromatography-Flame Ionization Detection (GC-FID) techniques may be deemed suitable. However, Liquid Chromatography-Mass Spectrometry (LC-MS) and Gas Chromatography-Mass Spectrometry (GC-MS) are usually the techniques of choice when higher specificity and sensitivity are required. Gas Chromatography-Electron Capture Detection (GC-ECD) techniques are commonly used for halogenated PGIs/GIs to enhance sensitivity and selectivity. Occasionally, some spectroscopic techniques like Nuclear Magnetic Resonance (NMR), light scattering, and Inductively Coupled Plasma-Mass Spectrometry (ICP-MS) are used in analyzing PGIs/GIs.
Packaging is one of the largest industry sectors in the world, worth several billions. There are three major types of pharmaceutical packaging, which are: solid packaging, semi-solids packaging and liquid packaging. The pharmaceutical packaging is a very profitable industry and it is estimated that for 2022 it will reach USD. 8.24 billion. Pharmaceutical packaging represents a meagre percentage of this colossal market. The Global Logistics Market is expected to grow at a CAGR of 7.0% from 2016-2021 and CAGR of 5.6% from 2021-2027. By 2020, pharma cold-chain logistics will be worth $16.7 billion, and non-cold chain at $77.1 billion. The market was estimated at $14.84bn in 2016 and is expected to grow to $28.75bn in 2027.
With more stringent compliance parameters set by the USFDA the quality assurance of pharmaceutical products is ensured. In addition to cGMP, GLP and GCP practices as per the US Federal law pharma products should comply with 21CFR regulations. Also on a regular basis the FDA organizes compliance programs for the pharma industries in program areas like Biologics (CBER), Bioresearch Monitoring (BIMO), Devices/Radiological Health (CDRH), Drugs (CDER), Food and Cosmetics (CFSAN), Veterinary Medicine (CVM). The results of regulatory audits NAI – No Action Indication, VAI – Voluntary Actions Indicated, OAI – Official FDA Action Indicated are also critical to decide by auditors in regards to compliance matters and call for several challenges to overcome by the manufacturers.
The global clinical trials market size was valued at USD 40.0 billion in 2016 and is expected to grow at a CAGR of 5.7% until 2025. The demand for biosimilars testing is expected to increase in the U.S. The interventional study design is the most prominent method of conducting clinical trials across with globe. According to statistics provided by the U.S. FDA, over 126,000 trials are currently being conducted by means of this method. Based on indication, the oncology segment is anticipated to witness the fastest growth. According to various sources, more than USD 38.0 billion is currently spent by the healthcare industry towards preclinical and clinical development of oncology therapy products. Hence, it is anticipated to grow at a lucrative CAGR and contribute over USD 15.0 billion towards the clinical trials market by 2025. MENA’s clinical trial revenues is expected to increase almost 10-fold over the next decade, which will build an annual market of about $1 billion.
Two powerful megatrends — dramatic deceleration in U.S. market growth and significant restructuring of the healthcare system — are at play in the U.S. pharmaceuticals industry. The U.S. pharmaceutical market is the world’s most important national market. Together with Canada and Mexico, it represents the largest continental pharma market worldwide. The United States alone holds over 45 percent of the global pharmaceutical market. In 2016, this share was valued around 446 billion U.S. dollars. The biopharmaceutical companies in the United States exported goods in the amount of some 31 billion U.S. dollars during 2016. In the United States, there are an estimated 100,000 OTC drug products marketed and sold in a variety of outlets, such as pharmacies and convenience stores. TH revenue for the OTC drugs also add to the pharma market growth. Top markets for pharmaceutical products continue to be developed countries in Western Europe, East Asia, and North America with high per capita spending on healthcare, growing elderly populations, and advanced regulatory systems. Though ranked lower, there are growing opportunities in developing countries like China as incomes and healthcare spending increases. The pharmaceutical sector has consistently been one of the most R&D intensive industries in the United States. The research-based industry generally allocates around 15 to 20 percent of revenues to R&D activities and invests over $50 billion on R&D annually.
Track 15: Pharmacoeconomics:
Health economics is a tool to help us prioritise different and sometimes competing health care interventions for these fixed resources and, in doing so, health care is treated as a commodity like any other. Knowledge of health economics coupled with political insight is essential to understand resource allocation and expenditure in a modern health care system. Pharmacists, with their unique knowledge of medicine, are crucial in using pharmacoeconomic analysis to influence expenditure and distribution of resources on medicines. Design and management of pharmacoeconomic studies
- cost and burden of illness studies,
- drug utilization,
- budget impact analysis,
- modeling and simulations
are very important in today’s pharmaceutical market. Moreover pharmacoeconomic approach towards
- Management of Consensus Meetings (Advisory Boards, Delphi Panels, etc.)
- Re-analysis of trials
Implementation and customization with local data of pharmacoeconomic models
have greatly aided the pharma industries.
Particle Sciences has a great deal of successful experience in the development of successful delivery systems for many types of APIs and sites of action. Drug delivery technologies enhance drug absorption, efficacy, and patient experience. Enhancing the drug delivery technology of final pharmaceutical formulation can increase its commercial success. Drug delivery systems have been used in delaying drug clearance processes. Drug delivery approaches have their advantages and limitations. Drug delivery approaches include solubilization, permeability enhancement, modified release (MR). Researchers discover new drugs through insights into a disease process that allow researchers to design a product to stop or reverse the effects of the disease. Once researchers identify a promising compound for development, they conduct experiments to gather information on how it is absorbed, distributed, metabolized, and excreted, best dosage, Side effects, how it interacts with other drugs and treatments and its effectiveness as compared with similar drugs.
The global drug delivery technology market is projected to reach USD 1,669.40 Billion by 2021 from USD 1,179.20 Billion in 2016, at a CAGR of 7.2% during the forecast period. The North American drug delivery technologies market is projected to reach USD 758.7 Billion by 2021 from USD 520.0 Billion in 2016, at a CAGR of 6.5% during the forecast period. Bringing one new drug to the public typically costs a pharmaceutical or biotechnology company on average more than $1 billion and takes an average of 10 to 15 years. Each drug undergoes a stringent process of discovery, development, approval and finally, public use.
Pharmaceutical nanotechnology is most innovative field in the pharmaceutical industry. Nano technology is dealing with new emerging technologies. Application of nanotechnology in imaging, diagnostics and therapeutics is considered as an important factor. The drug delivery system positively impacts the rate of absorption, distribution, metabolism, and excretion of the drug or other related chemical substances in the body. Within regulatory boundaries thermodynamics and nanotechnology are considered to be evolving tools to provide new and integrated knowledge for the production of new medicines.
Nanotechnology speaks to a stage for creating progressive changes and enhancements to a wide range of parts of pharmaceutical assembling. Pharmaceutical nanotechnology has provided fine-tuned diagnosis and focused treatment of disease at a molecular level. Nano technology is having an utmost importance in Gene therapy.
A particle with at least one dimension less than 100nm is a nanoparticle. They are composed of synthetic or semisynthetic polymers carrying drugs or proteinaceous substances. Nanoparticles have developed as capable vehicles to deliver drugs in the body. Nanoparticles comprising encapsulated, dispersed, absorbed or conjugated drugs have exceptional characteristics that can lead to higher performance in a variety of dosage forms. Nanoparticles are one of the novel drug delivery systems which can be of potential use in controlling and targeting drug delivery as well as in cosmetic textiles and paints. There are recent developments in the use of nanoparticles as drug delivery systems to treat a wide variety of diseases.
Non-prescription medicines, commonly known as over the counter or OTC medicines, are used for treatment. Sales of over the counter medicines in pharmacy and grocery outlets reached £1268 5 million in 1994 about a third of the NHS drugs bill of C3 6 billion. In the late 1980s the government fuelled the over the counter market by making it easier to reclassify certain medicines from prescription only status to allow over the counter sale in pharmacies. Although all non-prescription medicines are required to hold a product licence, few have been evaluated in formal clinical trials in the setting in which they will be used. As a result many non-prescription products sold by pharmacists have been criticised for their lack of effectiveness. There are three legal categories of medicines prescription only medicine (POM), pharmacy medicine (P), and general sales list medicine (GSL); the last can be sold from outlets including supermarkets and drugstores. The principle of a class of medicines whose sale requires the supervision of a pharmacist is not unique to the United Kingdom.
International Organization for Standardization (ISO) 9000 requirements do not have the same status of “the law” in the U.S. as do requirements listed in the Code of Federal Regulations (CFR). Because 21 CFR 210 and 211 have legal status, the U.S. Justice Department has extensive powers to ensure compliance. For example, product in the marketplace can be seized, fines can be levied, and personal liability can be assigned. So, management must understand that auditing must be taken seriously, and the requirements listed are just that – requirements. While audits are the common place in the pharmaceutical industry, the preparedness for those events varies. The companies that develop a risk-based approach to audits are able to remain competitive while meeting quality and government compliance standards on a regular basis. Conversely, the companies that have not implemented strong processes are putting themselves at risk for non-compliance. According to the Federal Food, Drug and Cosmetic Act, “Registered domestic drug establishments shall be inspected by the FDA at least once every two years.” Under some conditions the inspections may be even more frequent, As regulations become more stringent, regulatory authorities are likely to step up audits which is even more reason for companies to be prepared.
A biopharmaceutical, otherwise called a biologic therapeutic item or biologic, is any restorative item made in, extricated from, or semi orchestrated from organic sources. Not quite the same as synthetically incorporated pharmaceuticals, they incorporate immunizations, blood, or blood segments, allergenic, substantial cells, quality treatments, tissues, recombinant restorative protein, and living cells utilized as a part of cell treatment. Biologics can be made out of sugars, proteins, or nucleic acids or complex mixes of these substances, or might live cells or tissues. They are confined from normal sources—human, creature, or microorganism. Phrasing encompassing biopharmaceuticals fluctuates amongst gatherings and elements, with various terms alluding to various subsets of therapeutics inside the general biopharmaceutical class. Some administrative offices utilize the terms natural restorative items or remedial organic item to allude particularly to designed macromolecular items like protein-and nucleic acid–based drugs, recognizing them from items like blood, blood segments, or antibodies, which are typically extricated specifically from a natural source Gene-based and cell biologics, for instance, frequently are at the front line of biomedical research, and might be utilized to treat an assortment of therapeutic conditions for which no different medications are accessible.
Pharma Research 2019 Conference is a multidisciplinary program with broad participation with members from around the globe focused on learning about Pharma Research and Development and its advances. This is your best opportunity to reach the largest assemblage of participants from Pharma Research and Development community that is from academia, research entities, medical groups, related associations, societies and also from government agencies, pharmaceutical, biomedical and medical device industries.
Who should attend and Who You’ll Meet
Directors/Senior Directors/Executive Directors and Vice Presidents/Senior Vice Presidents/Executive Vice Presidents and Heads/Leaders/Partners of
- Pharma R&D
- CROs and CMOs
- Clinical Research Sites
- Pharma/Biotech and Medical Device industries
- Hospitals, Associations
Medical Directors, Principal Investigators, Methodologists, and other clinical research professionals along with Academicians: University Faculties like Directors, Senior Professors/Assistant Professors/ Associate Professor, Research Scholars, scientists who are related to clinical and medical research. Students also participate at this event as student delegates and young research forum (YRF).
We are delighted to all our Organizing Committee Members, Keynote Speakers, Speakers, Delegates, Students, Exhibitor and Media partners for making our Past Pharma Research 2018 Conference in USA Region with great Pride.
- International Conference & B2B on Pharma Research and Development, June06-07, 2018
- Venue: Doubletree by Hilton Hotel Philadelphia Airport , Address: 4509 Island Ave, Philadelphia, PA 19153, USA
Pharma Research 2018
Conference Series LLC Ltd hosted the “International Conference & B2B on Pharma Research and Development” (Pharma Research 2018) during June 06-07, 2018, at Doubletree by Hilton Hotel Philadelphia Airport, Address: 4509 Island Ave, Philadelphia, PA 19153, USA.
Pharma Research 2018 is specifically premeditated with a unifying axiom providing platform to widen the imminent scientific discoveries in the field of Pharmaceutical Research and Development and to deliver novel ideas besides incorporating better understanding of their role in Pharma, Drug Manufacturers, Business Management and Marketing. The scientific meeting has laid the path for the development and the validation of Pharmaceutical Research and Development under the theme of “Overcoming the challenges in pharmaceutical research”
Conference Series LLC Ltd is prerogative to thank the Organizing Committee, Editorial Board Members and Moderator – Dr. Hongbin Wang, California Northstate University, USA and Life Sciences, Austria, speaker participants, poster presenters and attendees for enormous support and participation in this grand venture.
The highlights of the meeting were the eponymous lectures, delivered by the following speakers:
Carmen Tamayo, Heterogeneity LLC, USA
Freddie Ann Hoffman, Heterogeneity LLC, USA
Gus R Rosania, University of Michigan, USA
Hai-Feng Ji, Drexel University, USA
Maysoon A Abujarad Alhuwitat, Independent Researcher, Jordan
Imeda Rubashvili, Tbilisi State University, Georgia
Rayhana Begum, Primeasia University, Bangladesh
Maysoon A Abujarad Alhuwitat, Independent Researcher, Jordan
Michael Chorny, University of Pennsylvania, USA
Hongbin Wang, California Northstate University, USA
Aysu Yurdasiper Erdem, Ege University, Turkey
Imeda Rubashvili, Ivane Javakhishvili Tbilisi State University, Georgia
Adella Aparna, Vaagdevi College of Pharmacy, India
Reveng Abdullah Abdulkareem, University of Duhok, Iraq
Deniz Sahin Tas, Gazi University, Turkey
Reveng Abdullah Abdulkareem, University of Duhok, Iraq
Maqsood Khan, Ziauddin University, Karachi, Pakistan
By the endless support of the Journal of Pharmaceutical Sciences & Emerging Drugs and Journal of Pharmaceutics & Drug Delivery Research. Conference Series LLC Ltd is pleased to announce our 2nd International Conference on Pharmaceutical Research & Innovations in Pharma Industry during April 19-20, 2019 at
Past Conference Keynote Speakers
Our warm gratitude to all the Honorable Keynote Speakers of Pharma Research 2018:
- Carmen Tamayo, Heterogeneity LLC, USA
- Freddie Ann Hoffman, Heterogeneity LLC, USA
- Gus R Rosania, University of Michigan, USA
- Hai-Feng Ji, Drexel University, USA
- Michael Chorny, University of Pennsylvania, USA and many more….
It is our Pleasure to show our appreciation towards our Chairs/Co-Chairs for the Sessions, namely
- Carmen Tamayo, Heterogeneity LLC, USA
- Freddie Ann Hoffman, Heterogeneity LLC, USA
- Hai-Feng Ji, Drexel University, USA
- Michael Chorny, University of Pennsylvania, USA and many more….
Conference series LLC Ltd expresses its gratitude to the conference Moderators, for taking up the responsibility to coordinate during the sessions, namely
- Hongbin Wang, California Northstate University, USA and many more....
Conference series LLC Ltd offers Special thanks to the organisations like Chemical Executive Club, Chemical Search. Framavita, VEAS, Crowd Revies, Manuscript Edit, BSTP and En-CPhI.cn personalities who supported the conferences by promoting in various modes online and offline which helped the conferences reach every nook and corner of the globe.
*** Bookmark Your Dates for the forthcoming Conference, We are hoping to see you soon! ***
Glance at Market of Pharma Research and Development
The United States is the world’s largest market for pharmaceuticals and the world leader in biopharmaceutical research.The global market for pharmaceutical Research was $70.1 billion in 2017 and $68.9 billion in 2019and this market is expected to rise at a compound annual growth rate (CAGR) of 2.3% from 2013 to 2018 and reach $77.1 billion by 2018 and the global advanced Pharma Research market should grow from roughly $178.8 billion in 2015 to nearly $227.3 billion by 2020, with a compound annual growth rate (CAGR) of 4.9%.The major attraction includes Liberty Bell, Franklin Institute, Eastern State Penitentiary, Barnes Foundation and many more.
Active Pharmaceutical Ingredient Market:
Transparency Market research states the opportunity in this market will be worth US$219.60 bn by 2023 from US$134.7 bn in 2015. Between the forecast period of 2015 and 2023, the overall market is expected to expand at a CAGR of 6.3%. Between the forecast period of 2015 and 2023, the overall market is expected to expand at a CAGR of 6.3%.
The global pharmaceutical excipients market is projected to reach USD 8.1 Billion in 2021 at a CAGR of 6.1% in the forecast period 2016 to 2021. The rising demand for new drug delivery systems, greater understanding of the functional benefits of excipients, growing pharmaceutical industry, and patent expiries of several blockbuster drugs are positively impacting the overall growth of the market.
Global Pharmaceutical excipients Market, by Region
- Rest of Europe (RoE)
- Rest of APAC
- Latin America
- Middle East & Africa
- Asia-Pacific (APAC)
- Rest of the World (RoW)
Major Marketing Associations around the Globe
- International Institute of Marketing Professionals (IIMP®)
- Marketing Power (American Marketing Association -AMA)
- American Branding Association (ABC)
- Canadian Marketing Association (CMA)
- Marketing Education Association (MEA)-USA
- Association for Consumer Research (ACR)
- The Asia-Pacific Professional Services Marketing Association (APSMA)
- Association of Internet Marketing and Sales (AIMS)-Canada
It's the delegate's responsibility to investigate the visa requirements for USA and to apply for a visa, if necessary. Individuals requiring an official Letter of Invitation from the conference organizers can request one by email by writing to us at [email protected].
To receive a Letter of Invitation, delegates, accompanying persons/children, student/post-doc/youth delegates and exhibitors must first register for the conference.
The registration fee minus a handling fee of USD 100 will be refunded after the conference if the visa was applied for in time and proof is shown that a visa could not be granted even though all requested documents were submitted. Refund requests must be made in writing and sent to the Pharma Research 2018 via email.
All expenses incurred in relation to the conference are the sole responsibility of the delegate. The Letter of Invitation does not guarantee an entry visa to USA. However, the conference organizers will not directly contact embassies and consulates on behalf of delegates.
The deadline for requesting a Letter of Invitation is one month before travelling to USA.
For conference attendance and participation only Business Visa should be applied. Contact your nearest travel agent/visa information center/US Embassy for the correct application form.
- Formulations and NNDS
- Drug discovery and NCEs
- Active Pharmaceutical Ingredients
- Quality by design(QbD) approach
- Good Manufacturing Practices (GMP)
- Regulatory Affairs
- Pharmaceutical Manufacturing, Scale Up and Tech transfer
- QC & QA: Quality control and Quality assurance
- Analytical strategies for pharmaceutical products
- Pharmaceutical Packaging and Logistics
- Regulatory Authority Compliance
- Clinical trials and Pharmacovigilance
- Pharma Market Research
- Pharmaceutical Research and Development
- Drug Delivery Technologies & Drug Designing and Development
- Pharmaceutical Nanotechnology: Challenges and Opportunities
- Use of Nanoparticles in DDS and Newer Methodologies
- Pharmaceutical Auditing for OTC Drugs
- Importance of Audit in Pharmaceutical Industry
- Biologics and Biosimilars
To share your views and research, please click here to register for the Conference.
All accepted abstracts will be published in respective Our International Journals.
- Journal of Pharmaceutical Sciences & Emerging Drugs
- Journal of Pharmaceutics & Drug Delivery Research
Abstracts will be provided with Digital Object Identifier by